Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) saw a large drop in short interest during the month of January. As of January 15th, there was short interest totalling 4,540,000 shares, a drop of 17.5% from the December 31st total of 5,500,000 shares. Based on an average daily volume of 1,310,000 shares, the short-interest ratio is currently 3.5 days.
Zentalis Pharmaceuticals Trading Down 12.2 %
Shares of Zentalis Pharmaceuticals stock traded down $0.23 during trading on Thursday, reaching $1.66. The company's stock had a trading volume of 3,656,997 shares, compared to its average volume of 2,910,479. Zentalis Pharmaceuticals has a one year low of $1.66 and a one year high of $18.07. The stock has a 50-day moving average price of $3.00 and a two-hundred day moving average price of $3.30. The stock has a market capitalization of $118.29 million, a P/E ratio of -0.67 and a beta of 1.86.
Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.36. As a group, sell-side analysts anticipate that Zentalis Pharmaceuticals will post -2.48 EPS for the current fiscal year.
Institutional Investors Weigh In On Zentalis Pharmaceuticals
Several institutional investors have recently modified their holdings of the business. Verition Fund Management LLC lifted its holdings in shares of Zentalis Pharmaceuticals by 172.1% during the 3rd quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company's stock valued at $5,536,000 after purchasing an additional 951,500 shares in the last quarter. Primecap Management Co. CA lifted its position in Zentalis Pharmaceuticals by 21.6% in the 3rd quarter. Primecap Management Co. CA now owns 1,498,030 shares of the company's stock valued at $5,513,000 after acquiring an additional 265,690 shares in the last quarter. GSA Capital Partners LLP boosted its stake in Zentalis Pharmaceuticals by 138.5% in the 3rd quarter. GSA Capital Partners LLP now owns 608,585 shares of the company's stock worth $2,240,000 after purchasing an additional 353,384 shares during the period. Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Zentalis Pharmaceuticals by 126.3% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 229,138 shares of the company's stock valued at $843,000 after purchasing an additional 127,868 shares during the period. Finally, XTX Topco Ltd lifted its holdings in shares of Zentalis Pharmaceuticals by 8.7% in the third quarter. XTX Topco Ltd now owns 194,062 shares of the company's stock valued at $714,000 after purchasing an additional 15,597 shares in the last quarter.
Analyst Ratings Changes
Several equities research analysts recently weighed in on the stock. Wells Fargo & Company reduced their target price on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an "equal weight" rating for the company in a research note on Thursday. HC Wainwright dropped their price objective on shares of Zentalis Pharmaceuticals from $20.00 to $10.00 and set a "buy" rating for the company in a research note on Wednesday. Guggenheim cut their price target on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a "buy" rating for the company in a research note on Friday, November 15th. UBS Group dropped their target price on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a "neutral" rating for the company in a report on Tuesday. Finally, Wedbush reaffirmed a "neutral" rating and issued a $4.00 price target on shares of Zentalis Pharmaceuticals in a research note on Friday, January 24th. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $8.24.
Get Our Latest Stock Report on ZNTL
Zentalis Pharmaceuticals Company Profile
(
Get Free Report)
Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.
See Also
Before you consider Zentalis Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zentalis Pharmaceuticals wasn't on the list.
While Zentalis Pharmaceuticals currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
